REXULTI is the first and only pharmacological treatment approved in the U.S. for agitation associated with dementia due to Alzheimer’s diseasePRINCETON, N.J. & DEERFIELD, Ill. (BUSINESS WIRE) Otsuka Pharmaceutical, Co. Ltd. (Otsuka) and Lundbeck LLC (Lundbeck) announce the U.S. Food and Drug Administration (FDA) h.
REXULTI is the first and only pharmacological treatment approved in the U.S. for agitation associated with dementia due to Alzheimer’s diseasePRINCETON, N.J .
This new treatment provides adults living with schizophrenia a long-acting formulation that offers flexible 1- and 2-month dosing intervals1 In a Phase 3 clinical trial, UZEDY demonstrated
This new treatment provides adults living with schizophrenia a long-acting formulation that offers flexible 1- and 2-month dosing intervals1
In a Phase 3 clinical trial, UZEDY demonstrated up to. | April 28, 2023